

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently amended) A transvaginal drug delivery system comprising:
  - (a) a deposition comprising an effective amount of said drug and, optionally, a wetting agent; and
  - (b) a polymeric support on which said deposition is deposited, wherein said polymeric support is in the form of a strip.
2. (Original) A delivery system according to claim 1 wherein said drug is selected from the following: nonsteroidal anti-inflammatory drug (NSAID), anti-prostaglandin, prostaglandin inhibitor, COX-2 inhibitor, local anaesthetic, calcium channel blocker, potassium channel blocker,  $\beta$ -adrenergic agonist, leukotriene blocking agent, smooth muscle inhibitor, vasodialator, hormone replacement drug, androgenic hormone and a drug capable of inhibiting dyskinetic muscle contraction.
3. (Original) A delivery system according to claim 2 wherein said NSAID is selected from the following: Aspirin, Ibuprofen, Indomethacin, Phenylbutazone, Bromfenac, Fenamate, Sulindac, Nabumetone, Ketorolac, and Naproxen;  
said local anesthetic is selected from the following: Lidocaine, Mepivacaine, Etidocaine, Bupivacaine, 2-Cholorprocaine hydrochloride, Procaine, and Tetracaine hydrochloride;  
said calcium channel antagonist is selected from the following: Diltizen, Israpidien, Nimodipine, Felodipine, Verapamil, Nifedipine, Nicardipine, and Bepridil;  
said potassium channel blocker is selected from the following: Defetilide, E-4031, Almokalant, Sematilide, Ambasilide, Azimilide, Tedisamil, RP58866, Sotalol, Piroxicam, and Ibutilide;

said  $\beta$ -adrenergic agonist is selected from the following: Terbutaline, Salbutamol, Metaproterenol, and Ritodrine;

said vasodialator is selected from the following: nitroglycerine, isosorbide dinitrate and isosorbide mononitrate;

said hormone replacement drug is selected from the following: estrogen or estrodiol and progestogen;

said androgenic hormone is selected from the following: testosterone and other androgenic hormones;

said COX-2 inhibitor is selected from the following: Celecoxib, Meloxicam and Flosulide; and

derivatives of any of the above drugs.

4. (Original) A delivery system according to claim 3 wherein said NSAID is naproxen or ibuprofen.

5. (Original) A delivery system according to claim 1 wherein the components of said deposition are dissolved in a solvent and the deposition is deposited by evaporation of said solvent.

6-7. (Cancelled).

8. (Currently amended) A delivery system according to ~~claim 7~~ claim 1 wherein said strip consists of one or more layers.

9. (Original) A delivery system according to claim 8 wherein said strip consists of 2-16 layers.

10. (Currently amended) A catamenial tampon for insertion in a human vagina comprising:

- (a) an inner core comprising an absorbent material;
- (b) an outer layer comprising a liquid-permeable material; and
- (c) a delivery system according to claim 1, wherein said delivery system is positioned between said inner core and said outer layer.

11. (Cancelled).

12. (Currently amended) A catamenial tampon according to ~~claim 11~~ claim 10 further comprising a polymeric water-impermeable film between said delivery system and said inner core.

13. (Original) A tampon according to claim 10 wherein said delivery system comprises a plurality of strips of the polymeric support.

14. (Original) A tampon according to claim 13 comprising 3 strips.

15. (Cancelled).

16. (Currently amended) A catamenial tampon according to ~~claim 15~~ claim 12 wherein said polymeric water-impermeable film comprises high-density polyethylene (HDPE).

17. (Currently amended) A method of transvaginal drug delivery comprising inserting a catamenial tampon into a vagina, wherein said catamenial tampon comprises:

- (a) an inner core comprising an absorbent material;
- (b) an outer layer comprising a liquid-permeable material; and
- (c) a delivery system according to claim 1, wherein said delivery system is positioned between said inner core and said outer layer.

Applicant : Simon Benita, et al  
Serial No. : 10/082,819  
Filed : February 25, 2002  
Page : 5 of 8

Attorney Docket No.: 13962-002001 / 137745.6 JP/dab

18. (Original) A method according to claim 17 wherein said drug is a NSAID.
19. (Original) A method according to claim 18 wherein said NSAID is naproxen or ibuprofen.